It Ain t Always About Pain. MNA Pharmacology Summit Tupelo, Mississippi Sueanne Davidson DNP FNP-BC
|
|
- Brianna Hines
- 5 years ago
- Views:
Transcription
1 It Ain t Always About Pain MNA Pharmacology Summit Tupelo, Mississippi Sueanne Davidson DNP FNP-BC
2 ADHD
3 ADHD ADD, ADHD, Hyperkinetic disorder - It gets confusing Condition has been known for over 100 years but different labels have been used In 1994, the DSM changed the name from ADD (Attention Deficit Disorder) to ADHD because of advances in research 2013 DSM updated diagnostic criteria
4 Types of ADHD Inattentive Hyperactive/Impulsive Combined (Hyperactive/Impulsive and Inattentive) ** Most common
5 ADHD In children hyperactivity usually predominates Adolescents often display oppositional and restless behavior Adults have more problems with attention
6 Overview Complex disorder of higher brain functioning Symptoms- Inattention, Impulsivity and Hyperactivity Must occur before age 12 Must continue at least 6 months Must cause significant impairment in social, academic or occupational functioning Must create problems in multiple settings (home and school) ** need two different informants
7 ADHD Serious Public Health Problem Large estimated prevalence- 12 million U.S adults ages have ADHD (CDC 2010) School age children 11% affected with 75% continuing to exhibit symptoms into adulthood Significant impairment- school performance, socialization, and occupational functioning Chronic condition requiring long term intervention
8 Screening Tools/Rating Scales NICHQ Vanderbilt Assessment Scale (Parent and teacher informant) ages 6-12 SNAP-IV Teacher and Parent Rating Scale- ages 6-18 Wender Utah Rating Scale - Adults
9 ADHD American Academy of Family Physicians survey estimated that 1/25 adults in US have ADHD Adults with ADHD had it in childhood regardless if diagnosis was made Adults with ADHD consistently have problems with interpersonal relationships/employment
10 Symptoms of ADHD in Adults Impatient/problems with driving Easily bored Short attention span are you listening to what I said Inner restlessness of thought and activity Fidgety Forgetful, losing things Chronically late/poor time managers Procrastinating, trouble starting a task Difficulty getting organized/managing money Many ideas at the same time Easily distracted/ Impulsive decisions/moody
11 Heredity Family Aggregation of Disorder Parent is ADHD 20-54% offspring will have ADHD 25-35% of Siblings 78-92% of Identical Twins 15-20% of Mothers 25-30% of Fathers Variation in ADHD symptoms is genetically influenced-
12 Heredity Heredity not a factor? These contribute to risk of ADHD to varying degrees Difficult pregnancies/deliveries/low birth weight Prefrontal lobe injury Prenatal ETOH/Tobacco use/abuse High lead levels Not supported by research- excessive TV viewing, poor parenting, family chaos or poverty
13 Overview ADHD Complex disorder of higher brain functioninginattention, motor over-activity and difficulty inhibiting behaviors Symptoms- Inattention, Impulsivity and hyperactivity Must occur before age 12 Continue at least 6 months Create problems in multiple settings
14 Types of ADHD Inattentive
15 ADHD Inattentive Type Symptoms for six months Lack of attention to detail Poor listener Failure to follow through tasks Lack of sustained attention Disorganized Loses things necessary Easily distracted Forgetful
16 Hyperactive/Impulsive Type
17 Hyperactive/Impulsive Type Hyperactive/Impulsive On the go Inappropriate running and/or climbing Leaves seat often Fidget/Squirms Difficulty with quiet activities Talks excessively Blurts answers Intrusive Can t wait turn
18 Disorders that may Accompany ADHD Learning Disabilities (25-35%) Anxiety or Mood Disorders (33%) Bipolar Disorder Tourette Syndrome (tics) rare Oppositional Defiant Disorder (33%) Conduct Disorder (20-40%)
19 Other ADHD like conditions Chronic Stress Psychological disorders- Depression/Anxiety Substance Abuse
20 Key Public Health Concerns Safety of Pharmacological interventionshealth risk and benefits Effectiveness of current interventions to reduce impairment associated with ADHD Access to diagnosis and appropriate interventions for individuals and families affected by disorder***
21 ADHD Prevalence
22 Increased identification and treatment Greater media interest Heightened consumer awareness Availability of effective treatments Less social stigma Understanding ADHD as biochemical disorder and not an out of control child disorder
23 Brain scans reveal ADHD differences Functional Imaging- views brain while it works Static imaging reveals Lobe reduction in ADHD individuals
24 ADHD Medication Stimulants Nonstimulants
25 ADHD Medication Current guidelines American Academy of Child and Adolescent Psychiatry- Use long acting Initiation of drug therapy Dosing Schedule
26 5 P s of Drug delivery system Pills- IR Methylphenidate and Amphetamines Pump- Like tube of toothpaste (Concerta) Pellet- Dissolve at different times Patch- Dermal delivery system (Daytrana) Prodrug- Amphetamine (Vyvance) nonabusable
27 ADHD Medications Stimulants- Methylphenidates and Amphetamines Nonstimulants- Nor epinephrine reuptake inhibitors, Alpha agonists, Trycyclic Antidepressants
28 Stimulants Pharmacodynamics- Dopamine agonist indirectly release and prevent reuptake of Dopamine, Nor Epinephrine and Serotonin in presynaptic nerve endings.
29 Stimulant effect on Neurotransmitters
30 What s the deal with MAO and MAOI s Monoamine Oxidase A- enzyme responsible for breakdown of Dopamine, Nor Epinephrine and Serotonin Monoamine Oxidase B- enzyme responsible for breakdown of Dopamine(more potent than MAO- A) and phenyl ethylamine (PEA)- has actions similar to amphetamines itself (thought to be involved with feelings of lust, confidence, obsession and sexuality Amphetamines in high doses can inhibit these enzymes leading to increased Dopamine..ect.
31 Genes and ADHD Dopamine transporter (DAT1) gene- thought to be involved with Dopamine and Norepinephrine transporters DBH gene- thought to create a chemical that converts Dopamine and Norepinephrine Dopamine receptor D4 (DRD4) gene- associated with dopamine receptors in the brain and sensitivity to dopamine
32 Stimulants Pharmacodynamics Dopamine,Norepinephrine and Serotonin nerve fibers connect these regions of the brain to the prefrontal cortex to coordinate thinking, feeling, and responding to external stimuli. Stimulants increase these neurotransmitters therefore improving communication
33 Mesolimbic Reward Pathway
34 Stimulants Pharmacokinetics- Rapid onset of action. Plasma levels peak 1-4 hours, half life 1-12 hours depending on immediate/extended release Metabolized in Liver/Excreted In Kidney
35 Stimulants Pharmacotherapeutics- Precautions/Contraindications- Heart, MAOI s, Pregnancy category C/Breastfeeding, glaucoma, drug interactions ( Coumadin & anticonvulsants) Adverse reactions- Insomnia, weight loss growth retardation***, irritability, blurred vision, headaches and paradoxical drowsiness
36 Methylphenidate Instant Release-Regular tablets- Ritalin, Methylin (chew tabs or solution). Available 5, 10, 20mg tablets* last 2-5 hours. Problem with peaks and valleys. Dosing inconvenience Adults mg/d in2-3 divided doses-max 60mg/d in divided doses Children > 6yrs 5mg bid before breakfast/lunch. Max 60mg/day in divided doses
37 Methylphenidate Intermediate acting extended release tablets- ( Ritalin SR, Methylin ER, Metadate ER, Metadate CD ) Ritalin SR- 20mg 1x/day in am lasts up to 8 hours(duration of effect corresponds to total daily Ritalin IR dose). Advantage- Instant release converted to sustained release by keeping same dosage, convenient and less peak/valley Disadvantage- takes 2-3 hrs before peak effect
38 Methylphenidate Long acting extended release- Capsule (Ritalin LA), Tablet (Concerta) Ritalin LA- 20, 30, 40 mg ER capsule 1x/day am Can open capsule and sprinkle med in applesauce Advantage- Provides ½ IR and ½ ER beads, (school/work issue solved) lasts up to 8 hrs, less insomnia and no conversion
39 Methylphenidate Concerta- 18mg 1x/day children & adolescents, 18-36mg 1x/day adults. Conversion 5mg IR BID/TID = 18mg q am 10mg IR BID/TID= 36mg q am 15mg IR BID/TID= 54mg q am 20mg IR BID/TID = 72mg q am Disadvantage-Do not crush, chew or divide Concerta- 22% IR, 78% ER over hours provides smooth drug release
40 Methylphenidate Quillivant - Liquid 20% IR, 80% ER Reconstituted = 25mg/5ml Ages 6 and greater- 20mg/day in am max is 60mg/day May give with or without food Onset of action within 45 minutes and lasts 12 hours
41 Methylphenidate Daytrana cm- reaches peak concentration 2hrs 12.5= 10mg delivered over 9 hrs Patches provide a much lower first pass effect Use if difficulty swallowing meds Alternate sites Hips and remove after 9hours Dermal Irritant
42 Abuse Potential High potential for abuse and addiction Crushed, snorted or injected = effect almost identical to cocaine One of top ten stolen Rx drugs in US Street names- Kiddie coke, Vitamin R and the R ball
43 Pearls Methylphenidates Ritalin IR- Abuse potential increases Ritalin = Abdominal pain in children Generic form is Cheap Concerta with smoother effect than Adderall XR Methylphenidate has best track record
44 Dexmethylphenidates Focalin, Dexedrine, Focalin XR, Vyvance, Focalin tablets- usually BID dosing Peds mg/day (start 2.5mgBID) Adults mg/day 4-6 hour duration of effect Can titrate 2.5mg/week for peds and 10mg/week for adults
45 Dexmethylphenidates Focalin XR- dose 1x/day in am lasts 12 hours Available 5mg, 10, 15, 20, 25, 30, 35, 40mg capsules Max 30mg/day peds, 40mg/day adults New to Methylphenidates- 5mg/day peds, 10mg/day adults On Methylphenidates- initiate with ½ current total daily dose Effects last up to 12 hours/2 distinct peaks 4 hours apart
46 Dexmethylphenidates Vyvance- 1x/day in am (lasts hours) Comes in 20mg, 30, 40, 50, 60 and 70mg Capsules Dosing Adults and Peds- 30mg q am Can titrate increments 10mg/week Max dose 70mg/day Prodrug- inactive requires vivo conversion
47 Pearls Dexmethylphenidates Propensity for abuse much less than Ritalin Take with or without food Can sprinkle Focalin XR and Vyvance over applesauce /dissolve Vyvance in water V yvance first non- abusable amphetamine ever invented Lack of worsening sleep quality with Vyvance Vyvance- Longest acting stimulant available**
48 Mixed Amphetamine Salts Adderall IR, Adderall XR Capsule Adderall IR tablet- 5mg, 7.5, 10, 12.5, 15, 20, and 30mg 5mg/day or BID- increase by 5mg/weekly with max 40mg/day Dose in am and additional dose at intervals 4-6hrs
49 Mixed Amphetamine Salts Adderall XR Capsules- 5mg, 10, 15, 20, 25, 30mg ( 2 beads- ½ immediately ½ 4 hrs later) Children- 10mg q am titrate up 5-10mg/week max dose 30mg/day Adolescents-10mg/day may increase to 20mg/day after 1 week Adults- 20mg/day adjust weekly- usual 60mg/day Can change from IR dose to XR dose at the same total daily dose taken once daily
50 Pearls Mixed Amphetamine Salts Studies suggest Adderall slightly more potent and longer period of efficacy especially at lower doses than Methylphenidates See more weight loss with Adderall than methylphenidate or atomoxetine Can take with or without food May see more aggression with Adderall in children and teens Watch Adderall with Ultram-Seizures/SSRI s
51 Non stimulant Strattera Pharmacodynamics /MOA- Selective inhibition of the pre-synaptic Nor epinephrine Transporters Pharmacokinetics Well absorbed. Maximum plasma concentration 1-2 hrs after dosing. Up to 24 hour symptom relief Metabolized by liver/excreted in kidney
52 Non stimulants Strattera- (Atomoxetine) 10mg, 18, 25, 40, 60, 80, 100mg First line treatment for adults with ADHD Children/ Teens < 154 lbs mg/lb. body weight- Increase to 0.6mg/lb. body weight- max 1.4mg/kg Adults > 154 lbs- 40mg q day or 20mg BID *May take 6-8 weeks to see effects Smooth delivery Side effects- Dry mouth, headache, nausea, decreased appetite, sexual dysfunction
53 Pearls Strattera Unique Medicaid approval < 12 yrs old* Less abuse potential than stimulants Offers 24 hr coverage Preferred over Amphetamines in patients with Psychiatric disorders & ADHD Take with or without food Can use with TICs as does not effect Dopamine Can refill over the phone- non scheduled drug Good choice if Depression or Anxiety with ADHD
54 Pearls Strattera Black Box warning- Children/Teens increase risk of suicidal thoughts or actions Can d/c without tapering in Adults Long term use has been shown to affect memory Monitor liver- may increase enzymes Swallow capsule whole do not open, crush/chew $$$$ Under patent till 2017 Headache and nausea most frequent complaint
55 Non stimulant Tenex/Intuniv Pharmacodynamics/MOA- Alpha 2 Adrenergic Agonist Stimulates alpha 2 Nor epinephrine receptors concentrated heavily in Prefrontal cortex Affecting post-synaptic alpha 2 receptors Pharmacokinetics- Well absorbed from GI Significant first pass effect
56 Non Stimulant Tenex/ Intuniv Pharmacotherapeutics- Contraindicated in recent MI, Coronary Insufficiency or Renal Impairment Side Effects- low BP, HR, Fainting, dizziness Sleepiness**, and nausea Guanfacine IR (Tenex)- safety and efficacy <12 not established. Take at HS Guanfacine ER (Intuniv) 1mg, 2, 3, 4mg- Max 4mg/day mg/kg/Day Take at am
57 Pearls Intuniv Not a scheduled drug/category B Avoid high fat meal- will raise blood levels Do not crush pill Mainly used as adjunctive therapy to treat Insomnia and behavioral problems/anger issues Taper dose decrements of 1mg q 3-7 days
58 Antidepressants TCA Antidepressants - used as both primary and adjunctive therapy in children/adults who fail response to stimulants. Desipramine and Nortryptyline affects Nor epinephrine reuptake Avoid in Cardiac Disease/Conduction abnormalities
59 Stimulants How do I prescribe DEA Schedule II drug/ Refills prohibited Pharmacy requires new original prescription every month DEA office of Diversion Control Code of Federal Regulations Section
60 Code of Federal Regulations Section Schedule II refilling prohibited May issue multiple Rx. authorizing patient to receive up to 90 day supply Each Rx for legitimate medical purpose by practitioner acting in usual course of practice Written instructions on each Rx. as to earliest date Pharmacist may fill Provider concludes giving multiple Rx. does not create undue risk of diversion/abuse Issuing multiple Rx. is permissible under state law Use sound medical judgment in determining how often to see patient when 90 day Rx. given
61 Bureau of Narcotics suggestions for Nurse Practitioners Apply for access to the Mississippi Prescription Monitoring Program (PMP) Be familiar with Practitoner s Manual on DEA Diversion Control website
The Use of ADHD Medication in the Pediatric Population
The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationHumberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor
The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More informationParents Guide to ADHD Medications. Copyright Child Mind Institute
Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive
More informationADHD Medications: Basics. David Benhayon MD, PhD
ADHD Medications: Basics David Benhayon MD, PhD Goals & Objectives Understand basic classes of stimulants and equivalents Be exposed to role of nonstimulant alternatives Discuss the role of therapy in
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationAttention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD
Attention Deficit Hyperactivity Disorder State of the Art Christopher Okiishi, MD What is ADHD? Three subtypes: Inattentive (under diagnosed, esp. in girls) Hyperactive Impulsive Combined Impairments must
More informationPharmacologic Management of ADHD
Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine
More informationStimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information
Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More informationADHD Medications Table
Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common
More informationDose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.
MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)
More informationA REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE
A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE OVERVIEW Review Stimulant Treatment for ADHD STIMULANTS
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 202 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationADHD: A Focus On Drug Therapy
ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90
More informationBehavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
More informationFocalin compared to concerta
Focalin compared to concerta Search FREE SHIPPING how does focalin compared to concerta. Free shipping, quality, privacy, secure. how does focalin compared to concerta. Compare Ritalin vs. Focalin. Focalin
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationADHD Part II: Managing Comorbities
ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have
More informationPractical care of the Child with ADHD Kristina Hingre MD
Practical care of the Child with ADHD Kristina Hingre MD Objectives Know the DSM 5 Criteria for diagnosis of ADHD Identify 4 Comorbidities of ADHD Be familiar with the common ADHD medications and Side
More informationADHD: Management Update
4/5/17 Conflicts of Interest ADHD: Management Update I have no conflicts to disclose. Jennifer R. Walton, MD, MPH, FAAP April 7, 2017 ADHD: DSM-5 Definition Objectives To briefly review ADHD diagnostic
More informationPrevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand
The 25th Federation Of Asian Pharmaceutical Association (FAPA) Congress 2014 Kota Kinabalu, Sabah, Malaysia 9th - 12th October, 2014 Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 2009 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationTreating Disruptive Behavior Disorders in Children and Teens. A Review of the Research for Parents and Caregivers
Treating Disruptive Behavior Disorders in Children and Teens A Review of the Research for Parents and Caregivers e Is This Information Right for Me? This information is for you if: A health care professional*
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More informationEvidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center
Evidence-Based Pharmacotherapy Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center CME Disclosure I have no personal financial relationships in any commercial interest related to
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
More informationWhat are the most common signs of ADHD? And what are the most common medication interventions?
What are the most common signs of ADHD? And what are the most common medication interventions? Bennett Gertz, MD, FAAP Developmental Behavioral Pediatrician Children s Developmental Health Services Albertina
More informationPsychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved.
Psychopharmacology of ADHD Persistence (Predicted Value) Persistence of ADHD Into Adulthood 90 80 70 60 50 40 30 20 10 0 NA 10 15 20 25 30 Age at Follow-Up Syndromatic Persistence Symptomatic Persistence
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationADHD PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH 27
ADHD PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH 27 Considering ADHD diagnosis? Problem from inattention/hyperactivity Consider comorbidity or other diagnosis: Oppositional Defiant Disorder Conduct
More informationEvaluation and Treatment of ADHD An Overview
Evaluation and Treatment of ADHD An Overview Kevin Ware, M.D. Vice Chairman, Dept. of Psychiatry Mount Carmel Medical Center Columbus, Ohio Objectives Describe the prevalence and characteristics of ADHD
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationWe ll Be Discussing. Pregnancy 4/24/2013
Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free monthly e-newsletter? We ll Be Discussing The safety and efficacy track
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMA_10.11.7 Effective Date: 07.16 Last Review Date: 04.18 Line of Business: Cenpatico Medicaid Arizona Revision Log See Important Reminder at the end of this policy
More informationADHD Medications & How They Work. Gail C. Rodin, Ph.D. January 21, 2008
ADHD Medications & How They Work Gail C. Rodin, Ph.D. January 21, 2008 Agenda How the (ADHD) Brain Works (or doesn t) Neurons and neurotransmitters NE & DA: the major players in ADHD Channel vs. state
More informationMethylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 5 Last Review Date: December 2, 2016 Methylphenidate
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate
More informationManagement of Pediatric Attention Deficit & Hyperactivity Disorder (ADHD) Clinical Practice Guideline MedStar Health
Management of Pediatric Attention Deficit & Hyperactivity Disorder (ADHD) Clinical Practice Guideline MedStar Health These guideli es are pro ided to assist physi ia s a d other clinicians in making decisions
More information5/16/2018. Pediatric Attention Deficit Hyperactivity Disorder: Do you get it?
Pediatric Attention Deficit Hyperactivity Disorder: Do you get it? Mashelle Jansen, DNP, FNP BC Clinical Assistant Professor SUNY Upstate Medical University ADHD is a Commonly diagnosed Childhood Neurodevelopmental
More informationAsk The Shrink: ADHD
Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'
More informationOptions for Medication Management: Rx and OTC/Natural Treatments AMY NEWMEYER MD CHKD DIVISION OF DEVELOPMENTAL PEDIATRICS MARCH 24, 2018.
Options for Medication Management: Rx and OTC/Natural Treatments AMY NEWMEYER MD CHKD DIVISION OF DEVELOPMENTAL PEDIATRICS MARCH 24, 2018 Disclosures I have no conflicts of interest to disclose 1 Objectives
More informationChild & Adolescent Psychiatry (a brief overview)
Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina
More informationPage: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.25 Page: 1 of 5 Last Review Date: June 19, 2015 Description Concerta / Daytrana / Metadate CD / Metadate
More informationPsychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition
Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition Presented by Cat Dang, D.O Medical Director - Insightful Minds, Inc. Objectives Evaluation process Pharmacology
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationConroe ADHD Solutions
Diagnosis and Medical Management of ADD/ADHD How do we make the diagnosis of ADD/ADHD? We are very careful to be sure we have the diagnosis correct before considering treatment. In the past there were
More informationAutism Spectrum Disorders & Attention Deficit Disorder in PEDIATRIC PRIMARY CARE. Disclosures
Autism Spectrum Disorders & Attention Deficit Disorder in PEDIATRIC PRIMARY CARE TIPS Conference March 22, 2019 Benjamin L. Handen, PhD, BCBA-D Professor of Psychiatry and Pediatrics Western Psychiatric
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More information35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
More informationManaging attention deficit in adults in your office
Managing attention deficit in adults in your office Nick Kates MB.BS FRCPC MCFP(hon) Chair, Dept. of Psychiatry, McMaster University Cross Appointment, Dept. of Family Medicine, McMaster University Quality
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationManaging the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center
Managing the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center Abstract: The majority of boys and many girls with fragile X
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
More informationClinical Policy: Atomoxetine (Strattera) Reference Number: CP.PST.17 Effective Date:
Clinical Policy: (Strattera) Reference Number: CP.PST.17 Effective Date: 08.01.17 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationBeyond the Practice Parameters
Volume 17 l Number 3 l Fall 2010 Attention Deficit Hyperactivity Disorder: Beyond the Practice Parameters By Shelly Flynn, RN, MA, ARNP Division of Pediatric Neurology, Behavior and Development University
More informationRecognition and Treatment of ADHD in Primary Care Settings. Disclosure 11/6/2013. Objectives
Southern California Permanente Medical Group Pediatric Symposium Hyatt, Long Beach CA. 11/1/13 Recognition and Treatment of ADHD in Primary Care Settings Martin T. Stein, M.D. Professor of Pediatrics Division
More informationTrouble shooting medication adjustment and side effect management in children with ADHD
Trouble shooting medication adjustment and side effect management in children with ADHD Drs. Joanna Holland and Sarah Manos 44 th Annual Dalhousie Spring Refresher April 5, 2018 Disclosure We have no disclosures
More informationHalf life of focalin xr
Cari untuk: Cari Cari Half life of focalin xr 24-12-2016 Find a comprehensive guide to possible side effects including common and rare side effects when taking Adderall XR (Amphetamine, Dextroamphetamine
More informationAttention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D.
Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D. PREVALENCE & STATISTICS 6-8% of all children have ADHD (CDC Statistical Data) Age of onset: 7 years old (Prior DSM-IV) 12 years old (Current
More informationAttention Deficit Hyperactive Disorder (ADHD)
E-Resource September, 2015 Attention Deficit Hyperactive Disorder (ADHD) Attention Deficit Hyperactivity Disorder (ADHD) is the most common childhood behavioral health concern noticed in primary care.
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 1: Stimulants Dr. Ajit Ninan & Joel Lamoure 1 Practical Psychopharmacology for More
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationRitalin mg equal to adderall
P ford residence southampton, ny Ritalin mg equal to adderall Snorting Ritalin will make you go through a pill every ten mi a, then 2 every 10. Try or Ritalin it got me good for three hours and wasn't
More informationIndividuals with attention-deficit/hyperactivity
3 W H A T W E K N O W Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience chronic problems with inattention and/or
More informationAutism: Improving Health Care Outcomes
AUTISM AWARESS CONFERENCE Lewis County Autism Coalition 23 September 2011 Autism: Improving Health Care Outcomes Glenn C. Tripp, M.D. Developmental Behavioral Pediatrics Medical Director, Developmental
More informationFocusing in on Adult ADHD
Focusing in on Adult ADHD Diagnosis, Psychopharmacology, and Therapeutic Interventions Sharon Praissman Fisher, MS, APRN-A, APRN-PMHNP Balance Point Wellness Disclosures I have no financial/professional
More informationFocusing in on Adult ADHD
Focusing in on Adult ADHD Diagnosis, Psychopharmacology, and Therapeutic Interventions Sharon Praissman Fisher, MS, APRN-A, APRN-PMHNP Balance Point Wellness Disclosures I have no financial/professional
More informationADHD:Updates and Practical Suggestions
:Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com
More informationAttention Deficit Hyperactivity Disorder A Neuro-Anatomical Approach to diagnosis and treatment
Attention Deficit Hyperactivity Disorder A Neuro-Anatomical Approach to diagnosis and treatment Damon Lipinski, Ph.D. Clinical Psychologist Center for Pediatric Neuropsychology What is Attention? Different
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationADHD: A Life Script from Conception to Adulthood
Page 1 Attention Deficit Hyperactivity Disorder A Life Script from Conception to Adulthood A life script from conception to adulthood. Elizabeth A. Montagnese, M.D. Child and Adult Psychiatrist Speaker:
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationADHD Explanation 5: Medications used in ADHD
ADHD Explanation 5: Medications The aim of treatment is efficient functioning and achieving goals in life It is most important to find the dose of medications that works best As children grow they may
More informationUpdate on Selecting and Prescribing ADHD medications. Disclosure. Basic assumptions. The future. Really nice review: 9/24/2015
Update on Selecting and Prescribing ADHD medications Tarah Kruger M.D. Sept. 18, 2015 Disclosure No actual or potential conflict of interest in relation to this program Objective: to learn the rationale
More informationSTRATTERA Generic name: atomoxetine hydrochloride
1 Medication Guide PV 5850 AMP STRATTERA Generic name: atomoxetine hydrochloride Read this information carefully before you start taking STRATTERA (Stra-TAIR-a) to learn about the benefits and risks of
More information17.9 Food Patients may take STRATTERA with or without food.
17.5 Priapism Rare postmarketing cases of priapism, defined as painful and nonpainful penile erection lasting more than 4 hours, have been reported for pediatric and adult patients treated with STRATTERA.
More informationDisorder (ADHD) in Adults
San Francisco Health Network Behavioral Health Services Medication Use Improvement Committee 1380 Howard St. 5 th Floor San Francisco, CA 94103 Edwin Lee Mayor Guideline for Evaluation and Treatment of
More informationWeek 2: Disorders of Childhood
Week 2: Disorders of Childhood What are neurodevelopmental disorders? A group of conditions with onset in the developmental period Disorders of the brain The disorders manifest early in development, often
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationConversion table methylphenidate to vyvanse
P ford residence southampton, ny Conversion table methylphenidate to vyvanse Lisdexamfetamine dimesylate is converted to dextoamphetamine and L- lysine, which is of ADDERALL XR (10, 20, or 30 mg), Vyvanse
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationProblem solving Memory Language Motivation Judgment Impulse control Social behavior Planning
Introduction to ADHD: learn about the impact, diagnosis, and features of ADHD Learn about the etiology of the disorder Learn about the comorbidities with ADHD Learn about the common medications used in
More informationADHD. Differential Diagnosis includes: Learning/language disorders Oppositional defiant disorder Conduct D/o Anxiety Depression Substance abuse
ADHD Child, parent or teacher concerns for hyperactivity or inattention Assessment including review of ADHD symptoms, standardized measure (e.g. Vanderbilt) of symptoms per teacher and parent report consideration
More information4/11/2018. Attention Deficit Hyperactivity Disorder. ADHD is not a real disorder. History of ADHD and Stimulants. Disclosure.
Disclosure I have no conflicts of interests to disclose Attention Deficit Hyperactivity Disorder No affiliations or financial disclosures with pharmaceutical manufacturers Off-label use of drugs will be
More informationUpdate on the Treatment of ADHD 2019
Update on the Treatment of ADHD 2019 James H. Beard, Jr., M.D, FAAP Developmental-Behavioral Pediatrician Division of Developmental Pediatrics The Rights of ADHD The right diagnosis of ADHD and co morbidities
More informationOhio Psychotropic Medication Quality Improvement Collaborative. Minds Matter. Toolkit. for You and Your Family. This is the property of
Minds Matter Ohio Psychotropic Medication Quality Improvement Collaborative Minds Matter Toolkit for You and Your Family This is the property of About Minds Matter Minds Matter is a project to help teens,
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationADHD across the lifespan
ADHD across the lifespan D A V I D J U S T I C E, M D F A P A M E D I C A L D I R E C T O R T A N D E M H E A L T H 1 Disclosure No significant relationships to disclose 2 Outline Diagnosing ADHD/ADD.
More information18 PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH ADHD
18 PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH ADHD Considering ADHD diagnosis? Problem from inattention/hyperactivity Consider comorbidity or other diagnosis: Oppositional Defiant Disorder Conduct
More informationADHD: Current Concepts & Controversies
ADHD: Current Concepts & Controversies Nathaniel M. Rickles, Pharm.D., Ph.D., BCPP Associate Professor of Pharmacy Practice & Administration Department of Pharmacy Practice Northeastern University School
More informationChelsea Murphy MS, NCC. Kennedy Health Systems
Chelsea Murphy MS, NCC Kennedy Health Systems What is ADHD? o Neurobiological Disorder deficit in the neurotransmitters (message senders within the brain) o Dopamine & Norepinephrine are not released as
More information